bbd: i think that the content of the rns has come as a bit of a surprise and is taking time to digest. some short term traders may be disappointed at the lack of a 20p rise and may be the ones selling. many lth are fairly max'd out with bprg so may not be buying significantly on this news. i also think that it is news that will take some time to digest. if the team had wanted impact then they could have easily separated the rns into 2 or 3 parts, perhaps releasing the trading update first. the trading update alone could have caused a good rise in the price but then the institutions may not have got their new shares at 47p.
[edit i don't think many are concerned about the dilution given we are gaining a profitable business with 6.5m euro revenue and 3m assets]
Bioprogress stock quotes
Bioprogress stock charts
Follow this thread
